bpc-157 human clinical trials safety regulatory status trial studies Here's a nice graphic on that you can hand out to patients who inquire about it. Thanks to Chris Centeno, M.D bpc-157 clinical humans safety – BPC-157 bpc-157 human clinical trial evidence

Currently, a series of phase 3 clinical trials, under the name of REDEFINE Program, are underway [13]

Calcaterra V, Tornese G, Zuccotti G, Staiano A, Cherubini V, Gaudino R, Fazzi EM, Barbi E, Chiarelli F, Corsello G, Esposito SMR, Ferrara P, Iughetti L, Laforgia N, Maghnie M, Marseglia G, Perilongo G, Pettoello-Mantovani M, Ruggieri M, Russo G, Salerno M, Striano P, Valerio G, Wasniewska M, Italian Academy of Pediatrics, Italian Society of Pediatrics (2024) Adolescent gender dysphoria management: position paper from the Italian Academy of Pediatrics, the Italian Society of Pediatrics, the Italian Society for Pediatric Endocrinology and Diabetes, the Italian Society of Adolescent Medicine and the Italian Society of Child and Adolescent Neuropsychiatry

Improvements in chronic fatigue due to B12 injections can be noticed as early as one week

Course usually lasts 4-6 weeks

Most people start BPC-157 at 200 to 500 mcg per day

It's the unit conversion step between milligrams and micrograms that introduces errors